Tesamorelin 2 mg provides one individually sealed lyophilised vial of the synthetic GHRH analogue, suited for preclinical GH axis research, GHRHR agonist studies, and controlled laboratory protocols requiring a single 2 mg research vial.
Tesamorelin’s trans-3-hexenoic acid N-terminal modification confers DPP-IV resistance and an extended half-life of approximately 26–38 minutes compared to around 7 minutes for native GHRH, while preserving full GHRHR agonist activity. The single-vial format is suitable for smaller-scale experiments, pilot studies, or protocols that do not require a multi-vial kit.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Tesamorelin 2 mg contains one lyophilised vial of research-grade synthetic GHRH analogue. It is designed for laboratory research involving GHRHR agonist activity, GH/IGF-1 axis signaling, and related preclinical study models.
Tesamorelin acts through GHRHR-mediated Gsα/cAMP/PKA signaling associated with growth hormone release. Its DPP-IV-resistant structure and extended plasma half-life of approximately 26–38 minutes make it useful for research protocols examining modified GHRH analogues and downstream GH/IGF-1 axis activation.
The single-vial format is particularly suited to exploratory studies, single-condition experiments, pilot protocols, or researchers who require a smaller quantity before scaling into larger study designs. Independently third-party HPLC-tested; COA available per batch.
